Please add to your safe senders list.

The SITC Immune Monitor

Support SITC    Membership    Meetings    About SITC    

January 2016 – In this Issue

Society Updates | Global Impact | Education & Events | Membership | Publications| Careers

A Message from the President

Dear Colleagues,

It is hard to believe that we are now into 2016. New this year, SITC has expanded its membership to include nurses, physician extenders, pharmacists, patients, and patient advocates. We welcome them to contribute their perspectives to the Society and join the record number of members we have today. You can help SITC expand its impact and continue on its upward trajectory by becoming an official member of the Society's growing network of leaders in the field.

As many of you know, U.S. President Barack Obama announced during his final State of the Union Address a “moonshot” to cure cancer, which entails doubling the progress in cancer research and treatment over the next five years. To launch this initiative, current Vice President Joe Biden is focusing on greater allocation of resources and increased multi-stakeholder collaborative efforts.

The Society for Immunotherapy of Cancer (SITC) recognizes that collaboration is key to advancing the science and application of cancer immunotherapy—and cancer care as a whole. I am proud to inform you that SITC leaders are at the forefront of this effort, working with our NCI and FDA colleagues, to promote the role of immunotherapy in this important national initiative.

As a core value of the Society, SITC brings together stakeholders spanning a wide breadth of specialties and professional roles from across the globe to engage in scientific exchange, networking, and education that lead to progress in the field. We are in a strong position to contribute to the moonshot initiative and we will count on your support at this historic time in the development of the field.

Together, our members and collaborative partners can one day make the word “cure” a reality for cancer patients everywhere. And, on behalf of the Society, I invite you to join us along the way.

Best regards,

Howard L. Kaufman, MD, FACS
SITC President

Society Updates

SITC 2016 Cancer Immunotherapy Fellowship Award Submission Portal Now Open

In concert with the Society’s mission to improve cancer patient outcomes through the development and application of cancer immunotherapy, SITC is presenting to student members several one-year fellowship opportunities, which were made possible through the generosity of AstraZeneca, EMD Serono, and Genentech. Applications will be accepted through Monday, March 7, 2016. Learn more and apply here.

Global Impact

Breast-Gynecological International Cancer Conference Sparks Cancer Immunotherapy Discussion in Egypt

Presented by the Breast-Gynecological International Cancer Society in collaboration with the Society for Immunotherapy of Cancer

The 8th Breast-Gynecological International Cancer Conference (BGICC) provided a platform for scientific exchange and outlined the status of problems relating to breast and gynecological cancers. The most recent international trends and initiatives for treatment were discussed, including immunotherapy for the first time ever in Egypt.

To learn more, download the report from Secretary General of the BGICC, Prof. Hesham Elghazaly (Ain Shams University), here.

Education & Events

Immuno-Oncology 360º

February 2-3, 2016 • The New York Academy of Medicine • New York, New York

Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer

Immuno-Oncology 360° combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology clinical trials. SITC President, Howard L. Kaufman, MD, FACS (Rutgers Cancer Institute of New Jersey), will participate as a speaker and panelist alongside other leaders in the field. Learn more and register here.

II Translational Forum on Cancer Immunotherapy (FIT-Cancer II)

March 11-12, 2016 • Seville, Spain

Presented by the Spanish Group for Immuno-Biological Therapies in Cancer (GÉTICA) in collaboration with the Society for Immunotherapy of Cancer

This program, held in Spanish, aims to guide oncologists in integrating immunotherapy into the therapeutic strategy for cancer patients. Learn more and register here.

Third Immunotherapy of Cancer Conference (ITOC-3)

March 21-23, 2016
Munich Tumour Center • Munich, Germany

Presented by the Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer

ITOC-3 will provide a forum for discussion of early clinical drug development and address the unique challenges of drug development. As such, the conference attracts a multi-stakeholder attendance, connecting preclinical and clinical scientists, clinicians, healthcare professionals, academia, and other stakeholders who are involved in the development of novel anticancer agents. Learn more and register here.

Immunotherapy Biomarkers 2016: Overcoming the Barriers

Cosponsored with the National Cancer Institute

Friday, April 1, 2016 • 8 a.m. – 5 p.m.
National Institutes of Health Campus • Bethesda, Maryland

"Cancer immunotherapy biomarkers are an area of critical need in the field," states SITC Vice President and SITC Immune Biomarkers Task Force Chair, Lisa H. Butterfield, PhD. "They provide insight into mechanism of action, and can help predict who should be enrolled into clinical trials, or at least who is likely to benefit. At this meeting, the SITC Immune Biomarkers Task Force Working Groups will present their summaries of the state of the field, identify hurdles, highlight new opportunities and make recommendations, all in a one day program."

Learn more and register here.

Cancer Immunotherapy 101 is Headed for Milwaukee, Wisconsin

Thursday, April 7, 2016 • 5 – 8:45 p.m.
Hilton Milwaukee City Center

Part of the Advances in Cancer ImmunotherapyTM series, this introductory, CME- and CE-certified program will provide clinical oncologists, nurses, pharmacists, and the entire team involved in treating cancer patients with a greater understanding of cancer immunotherapies, their therapeutic effectiveness, and the appropriate selection and management of patients.

Learn more and register here.

Can't make it to Milwaukee? More dates and locations are available!

Save the Dates for SITC 2016 – November 9-13, 2016

Gaylord National Hotel & Convention Center • National Harbor, Maryland

Mark your calendars for SITC's 31st Annual Meeting & Associated Programs! Known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, this is the conference you don't want to miss. Learn more.

Membership Makes a Difference

Join Today!

SITC is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy. As a member, you will join a growing network of nearly 1,300 basic and translational scientists, practitioners, healthcare professionals, government leaders, and industry professionals worldwide.

There are several membership categories including: Regular, Affiliate, Allied Health, Emeritus, Nurse and Physician Extender, Patient and Patient Advocate, Pharmacist, and Scientist-in-Training/Student memberships. To learn more about these categories, and to apply, visit the Membership page.

Already a Member? Don't Forget to Renew!

Continue receiving the valuable benefits listed below by renewing for 2016 now.

  • Waived article processing charges when you submit research to the Journal for ImmunoTherapy of Cancer—SITC’s official open access, peer reviewed journal ($2,500 USD value)
  • Reduced registration rates for all SITC educational programs and activities, including our Annual Meeting & Associated Programs, and free access to speaker presentations and slides from archived SITC live events
  • Eligibility to apply for SITC fellowships and grants, available exclusively to SITC members
  • Access to our membership directory, available only through the “Members Only” section of our website

Renew your membership here.

Call for Volunteers

SITC is a member-driven organization that relies on the tremendous efforts of committee volunteers to develop new recommendations for projects, programs, policies and strategies to improve the experience of the Society members, meeting attendees, and stakeholders in the field.

There are many exciting opportunities to get involved. For example, we currently have openings on the Communications, Website, and Social Media Committees, and you could be asked to:

  • Share insights and offer strategic direction for key messaging in order to effectively reach target audience(s)
  • Vet newsworthy content and identify key trends from the field
  • Provide review of copywriting that includes scientific content to ensure accuracy and unbiased positioning of the Society
  • Provide input on current and future content, format, and functionality of the Society website
  • Identify and implement strategies for member recruitment and retention
  • ... and more!

In 2015, over 500 individuals served on SITC committees and task forces. To join them in shaping the Society, renew your dues or become a SITC member, and complete and return this volunteer application form. Learn more here.

Publications & Resources

Journal for ImmunoTherapy of Cancer, the Resource for Cutting-Edge Science in the Field

Journal for ImmunoTherapy of Cancer (JITC) is SITC's official open access, peer-reviewed journal. It encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research to clinical application. As the global voice of the Society, JITC is the resource for SITC publications. 

Additionally, JITC features monthly technology primers produced by the SITC Immune Biomarkers Task Force. A hot topic in the field, these papers examine the latest in biomarker technologies for cancer immunotherapy. Access the articles here, and join us in Bethesda, Maryland on April 1 for Immunotherapy Biomarkers 2016: Overcoming the Barriers. 

Interested in publishing in JITC? Become a SITC member to receive waived article processing charges for papers accepted through 2016. Submit your manuscript here.

Latest Career Opportunities from SITC's Job Board

Scientist I, Immuno-Oncology
MedImmune – Gaithersburg, Maryland

Post-Doctoral Research Fellow
Fred Hutchinson Cancer Research Center

Principal Scientist, Vaccine Immuno-Oncology
Pfizer, Inc. – La Jolla/San Diego, California

Postdoctoral Fellow – Laboratory of Tumor Immunology
Center for Cancer Research – Menlo Park, California

Postdoctoral Fellow, Laboratory of Brain Tumor Immunotherapy, Department of Neurological Surgery
University of California, San Francisco

View All Job Board Listings

If you are interested in posting an open position to SITC's job board, please reference this agreement form for posting criteria or contact SITC at


Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email:

© 2016 Society for Immunotherapy of Cancer

Join us on:

Twitter  LinkedIn  YouTube  Oncology Tube

If you do not wish to be included in our mailing list, please forward this message to with the word "Remove" in the subject line.

Please add to your safe senders list.